Symphony Neuro Development Company

Symphony Neuro Development Company (SNDC) was a specialized biopharmaceutical company established as a project-specific vehicle to fund the clinical development of specific neuroscience assets. It was primarily formed through a strategic financing agreement between Symphony Capital and Bristol Myers Squibb to advance the development of several central nervous system compounds. The company's lead programs included the antipsychotic candidate asenapine and the sleep disorder treatment tasimelteon. Following the completion of the development programs and the exercise of buy-back options by the original partner, the entity's primary functions were concluded.